BridgeBio Pharma Inc logo

BBIO

BridgeBio Pharma Inc

$10.46

Earnings Summary

Revenue
$0.07Mn
Net Profits
$-0.01Mn
Net Profit Margins
-13.36%

Highlights

Revenue:

BridgeBio Pharma Inc’s revenue fell -99.86% since last year same period to $0.07Mn in the Q2 2022. On a quarterly growth basis, BridgeBio Pharma Inc has generated -95.65% fall in its revenue since last 3-months.

Net Profits:

BridgeBio Pharma Inc’s net profit jumped 99.99% since last year same period to $-0.01Mn in the Q2 2022. On a quarterly growth basis, BridgeBio Pharma Inc has generated 99.99% jump in its net profits since last 3-months.

Net Profit Margins:

BridgeBio Pharma Inc’s net profit margin jumped 92.51% since last year same period to -13.36% in the Q2 2022. On a quarterly growth basis, BridgeBio Pharma Inc has generated 99.88% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the BridgeBio Pharma Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.63
EPS Estimate Current Year
-0.63

Highlights

EPS Estimate Current Quarter:

BridgeBio Pharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.63 - a 43.24% jump from last quarter’s estimates.

EPS Estimate Current Year:

BridgeBio Pharma Inc’s earning per share (EPS) estimates for the current year stand at -0.63.

Key Ratios

Key ratios of the BridgeBio Pharma Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.35
Return on Equity (ROE)
-17.9
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. BridgeBio Pharma Inc’s return on assets (ROA) stands at -0.35.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. BridgeBio Pharma Inc’s return on equity (ROE) stands at -17.9.

Dividend Per Share (DPS):

BridgeBio Pharma Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-1.11
-1.35
-21.62%

Company Information

BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio's pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.

Organisation
BridgeBio Pharma Inc
Headquarters
Palo Alto, California, US
Employees
391
Industry
Health Technology
CEO
Neil Kumar